Interaction Checker

Interaksi Rimegepant

Rimegepant (Nurtec) memiliki 75 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 74 mayor, 1 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (74)

  • Abrositinibpenghambat JAKMayor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (label Rimegepant, Interaksi obat)

  • AmiodaronantiaritmiaMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Armodafinilstimulan SSPMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • AtazanavirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Mayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • DarunavirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Deferasirokssuplemen zat besiMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • DronedaronantiaritmiaMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • EfavirenzantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Eritromisinantibiotik makrolidaMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • EslikarbazepinantikonvulsanMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • EtravirinantiretroviralMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • EverolimusimunosupresanMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • FenitoinantikonvulsanMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • FenobarbitalbarbituratMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Flibanserindepresan SSPMayor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (label Rimegepant, Interaksi obat)

  • Flukonazolantijamur azolMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • FosamprenavirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • FosfenitoinantikonvulsanMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • GriseofulvinantijamurMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Imatinibpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • IsoniazidantibiotikMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Itrakonazolantijamur azolMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • KarbamazepinantikonvulsanMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Ketokonazolantijamur azolMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Klaritromisinantibiotik makrolidaMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • KlobazambenzodiazepinMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • KuinidinantiaritmiaMayor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (label Rimegepant, Interaksi obat)

  • Lapatinibpenghambat P-glikoproteinMayor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (label Rimegepant, Interaksi obat)

  • Ledipasvir dan sofosbuvirantivirusMayor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (label Rimegepant, Interaksi obat)

  • LenakapavirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Mayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Mirabegronagonis beta-adrenergikMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Mayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Mayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Modafinilstimulan SSPMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Nafsilinantibiotik penisilinMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • NefazodonantidepresanMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • NevirapinantiretroviralMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Nilotinibobat yang memperpanjang interval QTMayor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (label Rimegepant, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • OkskarbazepinantikonvulsanMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Mayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • PerampanelantikonvulsanMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Posakonazolantijamur azolMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • PrimidonantikonvulsanMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • PropafenonantiaritmiaMayor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (label Rimegepant, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • RifabutinantibiotikMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • RifampisinantibiotikMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • RifapentinantibiotikMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • RitonavirantiretroviralMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • SenobamatantikonvulsanMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • SiklosporinimunosupresanMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Sofosbuvir dan velpatasvirantivirusMayor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (label Rimegepant, Interaksi obat)

  • Suvoreksantsedatif-hipnotikMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Mayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • TikagrelorantiplateletMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • TopiramatantikonvulsanMayor

    • Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • Vorikonazolantijamur azolMayor

    • Strong CYP3A4 Inhibitors: Avoid concomitant administration. (label Rimegepant, Interaksi obat)

  • ZonisamidantikonvulsanMayor

    • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (label Rimegepant, Interaksi obat)

Interaksi moderat (1)

  • Dekstrometorfan dan kuinidinobat serotonergikModerat

    P-gp Inhibitors Concomitant administration of NURTEC ODT with potent inhibitors of P-gp (e.g., amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) may result in increased exposure of rimegepant. (label Rimegepant, Interaksi obat)

Periksa Rimegepant terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.